miR-150 在慢性髓性白血病中的表达：与伊马替尼反应的关系。

MiR-150 Expression in Chronic Myeloid Leukemia: Relation to Imatinib Response.

机构信息

Department of Clinical Pathology, Faculty of Medicine, Kafr El-Sheikh University, Kafr El-Sheikh, Egypt.

Department of Clinical Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt.

出版信息

Lab Med. 2022 Jan 6;53(1):58-64. doi: 10.1093/labmed/lmab040.

DOI:10.1093/labmed/lmab040

PMID:34350970

Abstract

OBJECTIVE

To assess the circulating micro-RNA-150 (miR-150) expression in patients with chronic myeloid leukemia (CML) in relation to imatinib response.

METHODS

Sixty patients with CML and 20 age- and sex-matched control subjects were enrolled. Circulating miR-150 levels were assessed by quantitative real-time polymerase chain reaction on days 0, 14, and 90 of imatinib therapy for patients and once for control subjects.

RESULTS

The baseline miR-150 expression was significantly lower in patients with CML than in control subjects with subsequent elevation at 14 and 90 days after the start of imatinib treatment. Early treatment response (ETR) at 90 days was the main study outcome. The miR-150 expression had a significantly higher level in patients with CML with ETR. On multivariate analysis, miR-150 on day 14 was significantly related to ETR in patients with CML with predictive efficacy (area under the curve = 0.838, 72.9% sensitivity, and 84.2% specificity).

CONCLUSION

We found that miR-150 expression on day 14 of imatinib treatment is a useful early predictive candidate for imatinib response in patients with CML.

摘要

目的

评估慢性髓系白血病（CML）患者中循环 microRNA-150（miR-150）的表达与伊马替尼反应的关系。

方法

纳入 60 例 CML 患者和 20 名年龄和性别匹配的对照者。通过定量实时聚合酶链反应评估患者伊马替尼治疗第 0、14 和 90 天以及对照者单次的循环 miR-150 水平。

结果

CML 患者的基线 miR-150 表达明显低于对照者，随后在伊马替尼治疗开始后 14 和 90 天升高。90 天的早期治疗反应（ETR）是主要的研究结果。对 ETR 有反应的患者 miR-150 表达水平更高。多变量分析显示，第 14 天的 miR-150 与 CML 患者的 ETR 显著相关，具有预测效能（曲线下面积=0.838，敏感性为 72.9%，特异性为 84.2%）。